Merck Dip Buy Call: Pipeline Optimism vs. Structural Headwinds

What happened

The article recommends buying Merck on a pullback, highlighting a normalized P/E of 12, a 3% dividend yield, and pipeline potential including 20 potential blockbusters and the Terns acquisition as offset to Keytruda LOE. However, the DeepValue report maintains a WAIT rating with a base case of $125 and bear case of $95, emphasizing the $2.5B 2026 headwind, unresolved Gardasil China pause, and Keytruda concentration risk. While the article's dip-buy thesis may resonate with value and income investors, the structural risks from generic/IRA erosion and the lack of visibility on Gardasil restart temper conviction. The market currently prices a holding pattern, and the next 6-9 months will be critical to see if new launches and cost actions can offset headwinds before the 2028-2029 Keytruda exclusivity step-downs. Thus, the article's call does not invalidate the base case thesis but adds a time-sensitive trade around valuation support.

Implication

The article's optimistic view on pipeline and dividend yield presents a near-term valuation floor, but without observable progress on Gardasil resumption or launch revenue scaling, the structural imbalance between Keytruda dependence and post-2028 replacement remains unaddressed. True re-rating will require evidence that the $2.5B headwind is manageable and that new assets like Winrevair and Capvaxive deliver material revenue by 2027. The dip is likely to be a trading range rather than a trend reversal until those catalysts materialize.

Thesis delta

The bullish Seeking Alpha article does not shift the central thesis that Merck is in a pre-LOE transition with uncertain execution. It reinforces that valuation support exists at current levels, but the key risk—Keytruda's 2028-2029 erosion and Gardasil's China pause—remains unmitigated. The call adds a short-term tactical layer but does not alter the WAIT rating.